Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.

    Summary
    EudraCT number
    2011-004712-32
    Trial protocol
    FR  
    Global end of trial date
    14 May 2014

    Results information
    Results version number
    v1(current)
    This version publication date
    31 Mar 2021
    First version publication date
    31 Mar 2021
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    UC-0130/1106
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01620242
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    UNICANCER
    Sponsor organisation address
    101 RUE DE TOLBIAC, PARIS, France, 75013
    Public contact
    Nourredine AIT RAHMOUNE, UNICANCER, 33 0171936704, n.ait-rahmoune@unicancer.fr
    Scientific contact
    Nourredine AIT RAHMOUNE, UNICANCER, 33 0171936704, n.ait-rahmoune@unicancer.fr
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    09 Dec 2015
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    27 Mar 2014
    Global end of trial reached?
    Yes
    Global end of trial date
    14 May 2014
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the efficacy of cabazitaxel in terms of non-progression at 6 weeks for the treatment of recurrent or metastatic head and neck cancer after failure of cisplatin, cetuximab and taxanes. Non-progression will be assessed after centralized review of CT-scans.
    Protection of trial subjects
    In order to ensure the protection of the rights, safety and well-being of trial subjects, this clinical trial was performed in compliance with the principles laid down in the declaration of Helsinki, good Clinical Practice and European regulation.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    06 Apr 2012
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety
    Long term follow-up duration
    1 Years
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    France: 31
    Worldwide total number of subjects
    31
    EEA total number of subjects
    31
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    24
    From 65 to 84 years
    7
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Recruitment only in France, first inclusion on 06 April 2012 and last inclusion occured on 19 April 2013

    Pre-assignment
    Screening details
    PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    cabazitaxel 25 mg/m2 every 3 weeks
    Arm description
    Patients will be treated with intravenous cabazitaxel 25 mg/m2 every 3 weeks (D1=D22) for 6 cycles. In absence of progression disease or unacceptable toxicity, the treatment could be continued until a maximum of 10 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    cabazitaxel
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Patients will be treated with intravenous cabazitaxel 25 mg/m2 every 3 weeks (D1=D22) for 6 cycles. In absence of progression disease or unacceptable toxicity, the treatment could be continued until a maximum of 10 cycles.

    Number of subjects in period 1
    cabazitaxel 25 mg/m2 every 3 weeks
    Started
    31
    Completed
    31

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall trial
    Reporting group description
    All patients included

    Reporting group values
    Overall trial Total
    Number of subjects
    31 31
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    24 24
        From 65-84 years
    7 7
        85 years and over
    0 0
    Gender categorical
    Units: Subjects
        Female
    7 7
        Male
    24 24

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    cabazitaxel 25 mg/m2 every 3 weeks
    Reporting group description
    Patients will be treated with intravenous cabazitaxel 25 mg/m2 every 3 weeks (D1=D22) for 6 cycles. In absence of progression disease or unacceptable toxicity, the treatment could be continued until a maximum of 10 cycles.

    Primary: Principal endpoint Non progression at 6weeks

    Close Top of page
    End point title
    Principal endpoint Non progression at 6weeks [1]
    End point description
    Non-progression at 6 weeks will be evaluated as per RECIST criteria (v1.1)
    End point type
    Primary
    End point timeframe
    6 weeks after treatment initiation
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Primary endpoint: The percentage of assessable patients with non progression disease at 6 weeks will be calculated using binomial estimates and reported with its 95% confidence interval (CI).
    End point values
    cabazitaxel 25 mg/m2 every 3 weeks
    Number of subjects analysed
    29
    Units: percent
        arithmetic mean (confidence interval 95%)
    27.6 (12.7 to 47.2)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Since inclution until 30 days after last treatment administration (no delay for related SAE)
    Adverse event reporting additional description
    The extraction of non serious AEs is not compatible with the filling of the form. For all non serious AEs, the number "1" has been reported in the "Subjects affected number" section and the "Occurrences all number" section.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    12
    Reporting groups
    Reporting group title
    all patients
    Reporting group description
    -

    Serious adverse events
    all patients
    Total subjects affected by serious adverse events
         subjects affected / exposed
    18 / 31 (58.06%)
         number of deaths (all causes)
    2
         number of deaths resulting from adverse events
    1
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    TUMOR PAIN
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular disorders
    JUGULAR VEIN THROMBOSIS
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    ANEMIA
         subjects affected / exposed
    2 / 31 (6.45%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    FEBRILE APLASIA
         subjects affected / exposed
    4 / 31 (12.90%)
         occurrences causally related to treatment / all
    4 / 4
         deaths causally related to treatment / all
    0 / 0
    FEBRILE NEUTROPENIA
         subjects affected / exposed
    3 / 31 (9.68%)
         occurrences causally related to treatment / all
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    CHRONIC PAIN
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    DISEASE PROGRESSION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    FACE EDEMA
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    GENERAL PHYSICAL HEALTH DETERIORATION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    INJURY ASSOCIATED WITH DEVICE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    DIARRHEA
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    DYSPHAGIA
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    HEMATEMESIS
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    INTESTINAL OBSTRUCTION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    ASPIRATION PNEUMONIA
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    DYSPNEA
         subjects affected / exposed
    3 / 31 (9.68%)
         occurrences causally related to treatment / all
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    PNEUMOPATHY
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    STAPHYLOCOCCUS AUREUS PNEUMONIA
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    RENAL INSUFFICIENCY
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    CATHETER INFECTION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    INFECTION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    LUNG INFECTION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    SEPTIC SHOCK
         subjects affected / exposed
    2 / 31 (6.45%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    1 / 1
    SEPTICEMIA
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    all patients
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    31 / 31 (100.00%)
    General disorders and administration site conditions
    DOULEURS TUMORALES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    FATIGUE/ASTHENIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    FIEVRE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    OEDEME PERIPHERIQUE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    INFLAMMATION DES MUQUEUSES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    FRISSONS
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    MALAISE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    CHOC SEPTIC
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Respiratory, thoracic and mediastinal disorders
    TOUX
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DOULEUR OROPHARYNGEE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    PNEUMOPATHIE DE DEGLUTITION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DYSPNEE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DESATURATION RESPIRATOIRE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HYPERSECRETION BRONCHIQUES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Cardiac disorders
    ARYTHMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    BRADYCARDIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Nervous system disorders
    CEPHALEES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    ANXIETE/DEPRESSION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    TROUBLES NEUROMOTEURS
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    TROUBLES NEUROSENSORIELS
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DYSGUEUSIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    VERTIGE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    LETHARGIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    SCIATIQUE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    NEUROPATHIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    PARESTHESIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DYSESTHESIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    TREMBLEMENTS
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Blood and lymphatic system disorders
    NEUTROPENIE FEBRILE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    ANEMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DIMINUTION DES LEUCOCYTES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DIMINUTION DES PLAQUETTES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DIMINUTION DES NEUTROPHILES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    LYMPHOPENIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DIMINUTION LYMPHOCYTES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HYPOALBUMINEMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Ear and labyrinth disorders
    ACOUPHENE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    BOURDONNEMENTS OREILLE DROITE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Eye disorders
    CONJONCTIVITE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    LARMOIEMENT AUGMENTE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Gastrointestinal disorders
    DIARRHEE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    NAUSEES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    VOMISSEMENTS
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    SECHERESSE DE LA BOUCHE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    REFLUX GASTRO-OESOPHAGIEN
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HEMORROIDES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HEMORRAGIE RECTALE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DOULEURS ABDOMINALES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DYSPHAGIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    CONSTIPATION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Skin and subcutaneous tissue disorders
    ERYTHEME
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    PRURIT
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DEMANGEAISON
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    FOLICULITE DU VISAGE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    ONYCHOPATHIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    NECROSE DE L'ORIFICE DE LA SONDE DE GASTROSTOMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Renal and urinary disorders
    DYSURIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    COLIQUE RENALE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HEMATURIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    POLLAKIURIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HYDRONEPHROSE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    RETENTION URINAIRE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    OBSTRUCTION URETRALE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    INCONTINENCE URINAIRE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    INSUFFISANCE RENALE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    INSUFFISANCE RENALE AIGUE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Musculoskeletal and connective tissue disorders
    ARTHRALGIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DOULEURS DORSALES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DOULEURS DES EXTREMITES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    SPASMES MUSCULAIRES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DOULEUR THORACIQUE MUSCULOSQUELETTIQUE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DOULEUR AU NIVEAU DU FLANC
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    MYALGIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DOULEURS OSSEUSES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DOULEURS JAMBES OSSEUSES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    TRISMUS
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DOULEURS EPAULES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Infections and infestations
    INFECTION DES VOIES RESPIRATOIRES
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    SEPTICEMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    MUCITE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    Metabolism and nutrition disorders
    ANOREXIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    DESHYDRATATION
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HYPERGLYCEMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HYPOKALIEMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HYPOALBUMINEMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HYPERKALIEMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1
    HYPERCALCEMIE
         subjects affected / exposed
    1 / 31 (3.23%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    10 Feb 2012
    Precision concerning the pregnancy test to be done before inclusion in the clinical trial
    22 May 2012
    Modification of the inclusion criteria in order to precise the cancer type included. Patient can be included after Platinium Failure (in stead of cisplatin Failure)
    16 Oct 2012
    Modification of the protocol according to the new smpc of the product

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 21:13:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA